Selective Androgen Receptor Modulator — Not Recommended
Matrix Advisory
SARMs are not recommended. Source data indicates poor risk-to-reward. Testosterone under medical supervision is the safer, more effective option.
RAD-140 (Testolone) is a selective androgen receptor modulator (SARM) developed as a potential alternative to testosterone replacement. It selectively binds androgen receptors in muscle and bone. Source assessment: "Garbage. Go with testosterone under supervision." The risk-to-reward profile does not justify use when supervised TRT is available.
Selectively activates androgen receptors in skeletal muscle and bone tissue while theoretically sparing prostate and other androgen-sensitive tissues. In practice, RAD-140 still causes significant hormonal suppression, liver stress, and many of the same side effects as anabolic steroids — without the decades of clinical data supporting testosterone use.
For Reference Only
Matrix does not recommend RAD-140. These doses are provided solely for harm-reduction awareness. Testosterone under medical supervision is the preferred protocol.
| Parameter | Details |
|---|---|
| Starting Dose | 5–10 mg daily |
| Moderate Dose | 10–20 mg daily |
| Route | Oral |
| Cycle Length | 6–8 weeks |
| Suppression | Suppresses hard — significant HPTA shutdown |
Mandatory Requirements
If used despite this advisory, the following are non-negotiable:
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any protocol.